.
.
.
.
Coronavirus

Drugmaker Sanofi to invest $475million in new Singapore vaccine production site

Published: Updated:

French drugmaker Sanofi said on Monday it would invest 400 million euros ($475.40 million) over five years in a new vaccine production site in Singapore.

The new site would provide Sanofi with the ability to produce innovative vaccines on a massive scale for Asia and respond to future pandemic risks, the company said in a statement.

For all the latest headlines follow our Google News channel online or via the app.

The project is expected to create up to 200 local jobs, it added.

Sanofi said it expected to start the construction of the site in the third quarter of 2021 and be fully operational in the first quarter of 2026.

“The Singapore site will complement Sanofi’s existing manufacturing capacities in Europe and North America and will become a regional center of excellence for vaccines productionin Asia," the company said.

Read more:

Drugmakers GSK, Sanofi begin new COVID-19 vaccine trial after setback last year

Sanofi confirms both COVID-19 shots could be available this year

Coronavirus: Why is it so hard to make COVID-19 vaccines and boost supplies?